Rochester, NY 7/11/2009 1:51:36 AM
Afternoon Results - LLY - Eli Lilly Announce Approval for Use of ALIMTA - Sourced WhisperFromWallStreet.com
Eli Lilly and Company
Afternoon Results - LLY - Eli Lilly Announce Approval for Use of ALIMTA - Sourced WhisperFromWallStreet.com
LILLY ELI CO,LLY
32.96 Down 0.04 (0.12%) 2:43pm ET
Eli Lilly and Companyc announced that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as monotherapy for maintenance treatment of patients with other than predominantly squamous cell histology in locally-advanced or metastatic non-small cell lung cancer (NSCLC), whose disease has not progressed immediately following platinum-based chemotherapy. This approval is based on data that showed pemetrexed improved overall survival in other than predominantly squamous NSCLC patients in the maintenance setting.
Last Trade: 32.95
Day's Range: 32.75 - 33.30
52wk Range: 27.21 - 49.78
Volume: 3,823,197
ABOUT
Eli Lilly and Company develops, manufactures, and sells pharmaceutical products worldwide. It offers neuroscience products to treat schizophrenia, manic episodes, and bipolar maintenance; depression and diabetic peripheral neuropathic pain; attention-deficit hyperactivity disorder in children, adolescents, and adults; depression, bulimia nervosa, and obsessive-compulsive disorders; and bipolar depression. The company?s endocrinology products are used for diabetes; type 2 diabetes; osteoporosis in postmenopausal women; osteoporosis in postmenopausal women and men at high risk for fracture; and human growth hormone deficiency and idiopathic short stature. It also provides oncology products to prevent pancreatic, metastatic breast, non-small cell lung, ovarian, and bladder cancers; malignant pleural mesothelioma; and colorectal cancers, as well as offers cardiovascular products for treating erectile dysfunction, atherothrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary invention and adults with severe sepsis at high risk of death.
---
WhisperfromWallStreet.com has a proven track record in picking winning stocks. While neither we nor anyone can offer a guarantee, we scan countless stocks on a daily basis to seek out those that have the greatest opportunity for gain. When we find these stocks, we immediately send an alert to our membership. Please feel free to track our results by joining our newsletter free. So far in 2009 we have sent over 40 alerts to our members with an average gain of over 80%.
Join our stock alert service free.
If you're an investor and interested in knowing which penny stocks are getting ready to run, sign up for our penny alerts at http://whisperfromwallstreet.com/
During 2009 we have sent out over 40 stock alerts resulting in an over 80% price gain. Sign up now FREE to track our results.
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT NOTE: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This press release should not be construed as a solicitation to buy or sell any particular stock or security. Neither WhisperfromWallstreet, nor any of its affiliates are registered investment advisors or broker dealers.
